Navigation Links
Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
Date:6/30/2008

Prescient Medical - SECRITT I Study to Evaluate Preventive Treatment of

Potentially Life Threatening Vulnerable Plaques

ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June 30 /PRNewswire/ -- An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam. This case marks the start of a pilot study, known as SECRITT I, designed to evaluate the vProtect(TM) Luminal Shield as a treatment for vulnerable plaques -- atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences. There are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe, every year. The sudden and unexpected passing of Tim Russert, host of NBC's Meet the Press, is thought to have been the result of a vulnerable plaque rupture.

The SECRITT investigators plan to place the self-expanding vProtect(TM) Luminal Shield in 15 patients with plaques identified as vulnerable by a combination of ultrasound and optical imaging techniques. These patients will be matched with 15 controls-patients who also have non-blood-flow-limiting plaques or "lesions" that have been identified as vulnerable-who will not receive the Shield. All patients are elective patients that have been referred to the cathlab for the treatment of a major lesion impairing normal cardiac function. All 30 patients will undergo follow-up diagnostic catheterizations 6 months after the initial treatment visit, at which time their lesions will be re-evaluated. This information will enable the investigators to observe whether the Shield has stabilized the target lesions.

According to Professor Patrick W. Serruys, MD, PhD, of Erasmus University, the SECRITT I trial represents the logical extension of modern cardiac medicine: "We are very good at op
'/>"/>

SOURCE Prescient Medical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...re/ -- New research has found that the availabilit...T) scanner in an emergency room can significantly ...a potentially life-saving treatment. Results of th...NSMC)-Salem Hospital in Salem, Mass., will be pres...cal Society of North America (RSNA). , , "T...
(Date:12/1/2008)...RNewswire-USNewswire/ -- A study has found that po... for imaging the breast, is not affected by either...factors that limit the effectiveness of standard m...ll be presented today at the annual meeting of the... , "The ability of PEM to detect cancer does...
(Date:12/1/2008)...irstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: ...f the world,s leading medical journals, results of... experimental compound tasimelteon (VEC-162). The...elatonin agonist tasimelteon (VEC-162) for transie... controlled multicentre trials." Results are repor...
(Date:12/1/2008)...rgeGen has announced that an oral,presentation of...d clinical,trial of TG101348 in myeloproliferativ... American Society of Hematology (ASH) Meeting. , ...:, Title: A Phase I Study of TG... JAK2-Selective Inhibitor, in Patients with,...
Breaking Medicine Technology:Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Helix BioPharma Announces 2411 4 Million Private Placement 7982 1Helix BioPharma Announces 2411 4 Million Private Placement 7982 2New England Peptide Names Director of Chemical Development 7977 1New England Peptide Names Director of Chemical Development 7977 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 1LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 2LIAI launches new division to look at novel approaches to heart disease and inflammation 5131 3Kazak apple research key to preventing blue mold 5127 1Kazak apple research key to preventing blue mold 5127 2
...cet on TMC125, an Investigational NNRTI,from Tibot...ta from two,ongoing Phase 3 studies (DUET-1 and DU...ts with documented non-nucleoside reverse,transcri...),resistance reached an undetectable viral load (d... 50 HIV-1 RNA copies/mL) with,TMC125 (etravirine),...
...6, 2007 /PRNewswire-FirstCall/ --,Genzyme Corp. an...Phase 3 clinical studies to assess the safety and ...non-antibiotic, polymer,therapy for patients with ...The second Phase 3 study of tolevamer liquid is fu...ear. , In this first Phase 3 study known as the Po...
Other Medicine Technology:TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
(Date:12/1/2008)...FirstCall/ -- The Ensign Group, Inc.,(Nasdaq: E...bilitation Center in,Pocatello, Idaho has success...,Medicaid Services, Special Focus program. , ...71213/LATH168LOGO ) , A clinical team led b...are,& Rehabilitation Center, completed the co...
(Date:12/1/2008)...e/ -- In the face of one of the most,severe econo...Health Board of,Directors has approved an investm... the Sutter Health Retirement Plan. Employee pensi...cks and bonds, have been among the biggest,casual...onservatively,invested, the Sutter Health Retirem...
(Date:12/1/2008)...ce of higher mortality and lower surgery rates in ...vere leakage may be related to the complexity of e...ding to findings of a Mayo Clinic study published ..., Mitral valve prolapse affects approximately 150...ac surgery, preferably valve repair rather than re...
(Date:12/1/2008)...iciaries for Par and Poker Celebrity Challenge for...e-USNewswire/ -- The Joyner-Walker Foundation toda...he Judeo Christian Health Clinic, Inc. as the Tamp...ty Challenge for Charity following a competitive a...iate that events like this give back to the host c...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2
...private company and was set up in 1994 in London. ...t has accepted to provide health care facility// f... three-year contract. It would provide General Pra...y 3 doctors and 7 nurses. It has won a ?5m contrac...
... study by rheumatologists at the University of Sou...te diet doesn’t increase the bone loss// for adult...t loss and it was published in the online issue of...l. A more broadly used weight reducing technique...
...r 15,000 people in Indonesia are being killed by d... jointly by National Narcotics Agency BNN// and th...rably large amount of money was being spent on dru...ple in the country. 'Some Rupiah12 trillions (loca...
...hniques, the Chinese Tai chi and various relaxatio...are programme held here on May 28 by the Rajayoga ...cted by Dr Girish Patel, secretary of the Medical ...rofession, the programme will deal with finding so...
Other Medicine News:Health News:Low Carbohydrate Diet Packs No Bone Loss 2
Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Ready to use: when presented in convenient, steady, Tipack racks, Diamond Tips are easy to pick up directly from the rack. To help prevent contamination, the 96 tips are loaded without manual interve
Medicine Products: